Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals
| Autor: | A Melikian, R Powell, Thomas J. Comstock, J Davis, L Manning, G Wright, Domenic A. Sica |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Urology Cmax Absorption (skin) Pharmacokinetics Oral administration Renal Dialysis Internal medicine Blood plasma medicine Humans Pharmacology (medical) Volunteer Chromatography High Pressure Liquid Pharmacology Methocarbamol business.industry General Medicine Endocrinology Female Kidney Diseases Hemodialysis business medicine.drug Protein Binding |
| Zdroj: | European journal of clinical pharmacology. 39(2) |
| ISSN: | 0031-6970 |
| Popis: | We determined plasma methocarbamol concentrations over 24 h following a 1.5 g methocarbamol dose (off-dialysis day) to 8 chronic haemodialysis patients and compared these results to those from 17 healthy male volunteers. The harmonic mean elimination half-life was similar between the two groups, 1.24 and 1.14 h, respectively. tmax and the weight-adjusted Cmax were 1.1 h and 27.0 mg.m-1 for haemodialysis patients and 1.1 and 23.1 mg.l-1 for normals. Relative systemic availability was assessed by comparing weight-normalized AUC x k10 products. These results indicate no significant differences with respect to methocarbamol absorption, with the relative systemic availability in patients being 113%. These data suggest that absorption and elimination of methocarbamol is similar between normal subjects and patients undergoing maintenance haemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink